ArticlePloS one2025
Optimizing reliability of RBC signal oscillation measures from hyperpolarized 129Xe MRI.
Article in PloS one, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Clinical research on pulmonary hypertension from a 2025 perspective: a narrative review.Journal of thoracic disease · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Recent advances to gas exchange hyperpolarized 129Xe MRI (Xe-MRI) have demonstrated that cardiogenic oscillations within the xenon red blood cell (RBC) signal are sensitive to pulmonary disease. Moreover, by implementing keyhole image reconstruction with gas exchange images collected using standard methodology, maps of regional oscillation amplitude can be generated. While such mapping has been demonstrated on a limited basis, validating these maps remains challenging due to the absence of easily measured biomarkers of pulmonary microvascular health. Moreover, as this is a very new technique, each of the previous implementations has used different methodology; it is unclear which of these methods provides optimal measures of regional oscillation amplitude. In this study, we evaluated oscillation mapping using the different published methods to determine which has the best same-day reliability. Because there are no easily obtainable measures of pulmonary vascular health, reliability serves as a valuable endpoint for validating that these maps are sensitive to real pulmonary physiology. We evaluated the same-day reliability of RBC oscillation measures in patients with systemic sclerosis (N = 6) and pulmonary arterial hypertension (PAH; N = 10), using single-time-point data from healthy volunteers (N = 9) to demonstrate "healthy" oscillation amplitude maps. Global measures of RBC oscillation amplitude (intraclass correlation coefficient; ICC = 0.88) had comparable reliability to standard xenon MRI measures (ICC ≥ 0.82). When examining oscillation mapping, some regional features showed disagreement across scans, but reliability of overall means was strong (ICC ≥ 0.86). Moreover, we show that recent advances in oscillation amplitude mapping for generating both amplitude and phase can provide equivalent maps to those methods that only provide amplitude. Overall, our findings demonstrate that Xe-MRI oscillation mapping has strong reliability when using optimized methods, even in participants with pulmonary disease.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.